S13 Ep50: SUPRAME Trial Propels the Development of TCR-Based Therapy in Cutaneous Melanoma: With Jason Luke, MD
In today’s episode, supported by Immatics, we spoke with Jason Luke, MD, about the development of the PRAME-directed T-cell receptor (TCR) T-cell therapy IMA203 in the ongoing phase 3 SUPRAME trial (NCT06743126) in patients with previously treated, unresectable or metastatic cutaneous melanoma.In o…
ASCO 2023 Highlights: THOR, INDIGO and ADAURA
The American Society of Clinical Oncology Annual Meeting 2023 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer. In this podcast, we hear from leading experts as they discuss some of the most groundbreak…
Forescape Radio #099
Support me on Patreon for exclusive content:
https://www.patreon.com/Enlusion
00:00 Enlusion — Prague Afterglow (Rise and Fall Remix) [JOOF Recordings]
06:57 Exotek — Daystar (Enlusion Remix) [Forescape Digital]
11:49 John 00 Fleming & Astral Projection — Transient Symbiosis [JOOF Recordings]
17:…
Immunotherapy at ASCO25: Drug Development, Melanoma Treatment, and More
Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting.
TRANSCRIPT
Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcas…
Advances in Immunotherapy for Melanoma and Beyond
Dr. Ryan Augustin and Dr. Jason Luke discuss neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, promising new TIL therapy for advanced melanoma, and the emerging role of CD3 engagers in treatment strategies.
TRANSCRIPT
Dr. Ryan Augustin: Hello, I'm Dr. Ryan Aug…
Immunotherapy at ASCO24: NADINA and Other Key Studies
Dr. Diwakar Davar and Dr. Jason Luke discuss advances in the neoadjuvant immunotherapy space that were presented at the 2024 ASCO Annual Meeting, including promising outcomes in high-risk melanoma from the NADINA trial, as well as other new treatment options for patients with advanced cancers.
…
ASCO24: The Future of Personalized Immunotherapy
Dr. Diwakar Davar and Dr. Jason Luke discuss key abstracts from the 2024 ASCO Annual Meeting that explore triplet therapy in advanced melanoma, TIL cell therapy in immune checkpoint inhibitor–naive patients, and other novel approaches that could shape the future of immunotherapy in melanoma and be…
Spotlight on Immunotherapy at ASCO23
Drs. Diwakar Davar and Jason Luke discuss KEYNOTE-716, KEYNOTE-942, RELATIVITY-047, and other key advances in melanoma, including the promise of mRNA vaccines in melanoma and potentially other cancers, as well exciting advances in neoadjuvant therapies across malignancies featured at the 2023 ASCO …
ASCO23: RELATIVITY-047, CheckMate-038, and Other Advances in Immunotherapy
Dr. Diwakar Davar and Dr. Jason Luke discuss advances in melanoma, including targeted therapy and the addition of LAG-3 inhibitors to checkpoint therapy, as well as promising checkpoint inhibitors in cutaneous squamous cell carcinoma and Merkel cell carcinoma in advance of the 2023 ASCO Annual Mee…
PODCASTIDE OTSINGUMOOTOR
Saate kasutada meie veebisaiti3,831,119taskuhäälingusaadete ja196,748,935osade otsimiseks inimeste, kohtade või teemade järgi.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
MUUDA
Aitäh, et aitad hoida podcastide andmebaasi ajakohasena.
